The effect of pomegranate products on glycemic profile in adults: a GRADE- assessed systematic review and dose-response meta-analysis of randomized controlled trials.

IF 2.2 Q3 NUTRITION & DIETETICS
Fatemeh Mohammadzaheri, Fatemeh Sheikhhossein, Amirhossein Hemmati, Seyed Mojtaba Ghoreishy, Mohsen Mohammadi-Sartang, Farideh Shiraseb, Seyed Ali Keshavarz
{"title":"The effect of pomegranate products on glycemic profile in adults: a GRADE- assessed systematic review and dose-response meta-analysis of randomized controlled trials.","authors":"Fatemeh Mohammadzaheri, Fatemeh Sheikhhossein, Amirhossein Hemmati, Seyed Mojtaba Ghoreishy, Mohsen Mohammadi-Sartang, Farideh Shiraseb, Seyed Ali Keshavarz","doi":"10.1186/s40795-025-01138-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pomegranate consumption may have a beneficial effect on glucose control and insulin resistance due to its bioactive compounds. However, the results of available clinical trials are inconsistent. To address these inconsistencies, we conducted a meta-analysis of 34 randomized clinical trials (RCTs) evaluating the effects of pomegranate on glycemic parameters in adults.</p><p><strong>Methods: </strong>A thorough search was conducted across multiple databases until December 2024 to identify trials that investigated the impact of pomegranate on glucose control and insulin sensitivity. We calculated the effect size, reported as the weighted mean difference (WMD) with 95% confidence intervals (CIs), based on the net changes in fasting blood glucose (FBS), insulin, HOMA-IR, and Hemoglobin A1c (HbA1c).</p><p><strong>Results: </strong>Among the 407 records, this meta-analysis included 34 eligible RCTs involving 1500 participants. Pomegranate consumption was significantly associated with a reduction in FBS (WMD: -3.036 mg/dl; 95% CI, -4.273 to -1.799, P < 0.001, Tau<sup>2</sup> = 6.039, I<sup>2</sup> = 89.22%), insulin (WMD: -0.967 IU/mL; 95% CI, -1.486 to -0.448, P < 0.001, Tau<sup>2</sup> = 0.761, I<sup>2</sup> = 83.82%), HOMA-IR (WMD: -0.338; 95% CI, -0.470 to -0.205, P < 0.001, Tau<sup>2</sup> = 0.031, I<sup>2</sup> = 84.96%), and QUICKI (WMD: 0.003; 95% CI, 0.001 to 0.006, P = 0.011, Tau<sup>2</sup> = 0.00, I<sup>2</sup> = 7.11%), whereas changes in HbA1c (WMD: 0.046, 95% CI: -0.207 to 0.298, P = 0.723, Tau<sup>2</sup> = 0.081, I<sup>2</sup> = 60.62%) were not statistically significant. The non-linear dose-response analysis showed a significant association between the pomegranate dose and FBS (P for non-linearity = 0.006). Also, the duration of pomegranate consumption showed a significant non-linear relationship with FBS (P for non-linearity = 0.022) and insulin (P for non-linearity = 0.030). We did not find a significant non-linear association between the dosage of pomegranate juice and FBS (P for non-linearity = 0.83), insulin (P for non-linearity = 0.51), and duration of pomegranate extract with FBS (P for non-linearity = 0.30).</p><p><strong>Conclusion: </strong>This meta-analysis suggests that the consumption of pomegranate products can result in positive effects on FBS, insulin levels, HOMA-IR, and QUICKI in adults. More RCTs with longer duration and larger sample sizes are needed to confirm these findings.</p>","PeriodicalId":36422,"journal":{"name":"BMC Nutrition","volume":"11 1","pages":"168"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40795-025-01138-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pomegranate consumption may have a beneficial effect on glucose control and insulin resistance due to its bioactive compounds. However, the results of available clinical trials are inconsistent. To address these inconsistencies, we conducted a meta-analysis of 34 randomized clinical trials (RCTs) evaluating the effects of pomegranate on glycemic parameters in adults.

Methods: A thorough search was conducted across multiple databases until December 2024 to identify trials that investigated the impact of pomegranate on glucose control and insulin sensitivity. We calculated the effect size, reported as the weighted mean difference (WMD) with 95% confidence intervals (CIs), based on the net changes in fasting blood glucose (FBS), insulin, HOMA-IR, and Hemoglobin A1c (HbA1c).

Results: Among the 407 records, this meta-analysis included 34 eligible RCTs involving 1500 participants. Pomegranate consumption was significantly associated with a reduction in FBS (WMD: -3.036 mg/dl; 95% CI, -4.273 to -1.799, P < 0.001, Tau2 = 6.039, I2 = 89.22%), insulin (WMD: -0.967 IU/mL; 95% CI, -1.486 to -0.448, P < 0.001, Tau2 = 0.761, I2 = 83.82%), HOMA-IR (WMD: -0.338; 95% CI, -0.470 to -0.205, P < 0.001, Tau2 = 0.031, I2 = 84.96%), and QUICKI (WMD: 0.003; 95% CI, 0.001 to 0.006, P = 0.011, Tau2 = 0.00, I2 = 7.11%), whereas changes in HbA1c (WMD: 0.046, 95% CI: -0.207 to 0.298, P = 0.723, Tau2 = 0.081, I2 = 60.62%) were not statistically significant. The non-linear dose-response analysis showed a significant association between the pomegranate dose and FBS (P for non-linearity = 0.006). Also, the duration of pomegranate consumption showed a significant non-linear relationship with FBS (P for non-linearity = 0.022) and insulin (P for non-linearity = 0.030). We did not find a significant non-linear association between the dosage of pomegranate juice and FBS (P for non-linearity = 0.83), insulin (P for non-linearity = 0.51), and duration of pomegranate extract with FBS (P for non-linearity = 0.30).

Conclusion: This meta-analysis suggests that the consumption of pomegranate products can result in positive effects on FBS, insulin levels, HOMA-IR, and QUICKI in adults. More RCTs with longer duration and larger sample sizes are needed to confirm these findings.

石榴产品对成人血糖谱的影响:一项GRADE评价的系统评价和随机对照试验的剂量反应荟萃分析。
背景:食用石榴可能对血糖控制和胰岛素抵抗有有益作用,因为它含有生物活性化合物。然而,现有的临床试验结果并不一致。为了解决这些不一致,我们对34项随机临床试验(rct)进行了荟萃分析,评估石榴对成人血糖参数的影响。方法:在2024年12月之前,对多个数据库进行了彻底的搜索,以确定研究石榴对葡萄糖控制和胰岛素敏感性影响的试验。基于空腹血糖(FBS)、胰岛素、HOMA-IR和血红蛋白A1c (HbA1c)的净变化,我们计算了效应大小,以95%置信区间(CIs)的加权平均差(WMD)报告。结果:在407份记录中,本荟萃分析纳入了34项符合条件的随机对照试验,涉及1500名参与者。石榴摄入与FBS (WMD: -3.036 mg/dl; 95% CI, -4.273至-1.799,P = 6.039, I2 = 89.22%)、胰岛素(WMD: -0.967 IU/mL; 95% CI, -1.486至-0.448,P = 0.761, I2 = 83.82%)、HOMA-IR (WMD: -0.338, 95% CI, -0.470至-0.205,P = 0.031, I2 = 84.96%)和QUICKI (WMD: 0.003;95% CI, 0.001 ~ 0.006, P = 0.011, Tau2 = 0.00, I2 = 7.11%),而HbA1c的变化(WMD: 0.046, 95% CI: -0.207 ~ 0.298, P = 0.723, Tau2 = 0.081, I2 = 60.62%)无统计学意义。非线性剂量-效应分析显示石榴剂量与FBS呈显著相关(非线性P = 0.006)。食用石榴时间与FBS(非线性P = 0.022)和胰岛素(非线性P = 0.030)呈显著的非线性关系。我们没有发现石榴汁的剂量与FBS(非线性P = 0.83)、胰岛素(非线性P = 0.51)和石榴提取物与FBS的持续时间(非线性P = 0.30)之间存在显著的非线性关联。结论:这项荟萃分析表明,食用石榴产品可以对成人的FBS、胰岛素水平、HOMA-IR和QUICKI产生积极影响。需要更多持续时间更长、样本量更大的随机对照试验来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Nutrition
BMC Nutrition Medicine-Public Health, Environmental and Occupational Health
CiteScore
2.80
自引率
0.00%
发文量
131
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信